|
|
| PMID |
|
|
| TITLE |
|
| Specificity in genetic and environmental risk for prescription opioid misuse and heroin use. |
|
| ABSTRACT |
|
| BACKGROUND |
NlmCategory: BACKGROUND |
| Many studies aggregate prescription opioid misuse (POM) and heroin use into a single phenotype, but emerging evidence suggests that their genetic and environmental influences may be partially distinct. |
| METHODS |
NlmCategory: METHODS |
| Many studies aggregate prescription opioid misuse (POM) and heroin use into a single phenotype, but emerging evidence suggests that their genetic and environmental influences may be partially distinct. In total, 7164 individual twins (84.12% complete pairs; 59.81% female; mean age = 30.58 years) from the Australian Twin Registry reported their lifetime misuse of prescription opioids, stimulants, and sedatives, and lifetime use of heroin, cannabis, cocaine/crack, illicit stimulants, hallucinogens, inhalants, solvents, and dissociatives via telephone interview. Independent pathway models (IPMs) and common pathway models (CPMs) partitioned the variance of drug use phenotypes into general and drug-specific genetic ( ), common environmental ( ), and unique environmental factors ( ). |
| RESULTS |
NlmCategory: RESULTS |
| Many studies aggregate prescription opioid misuse (POM) and heroin use into a single phenotype, but emerging evidence suggests that their genetic and environmental influences may be partially distinct. In total, 7164 individual twins (84.12% complete pairs; 59.81% female; mean age = 30.58 years) from the Australian Twin Registry reported their lifetime misuse of prescription opioids, stimulants, and sedatives, and lifetime use of heroin, cannabis, cocaine/crack, illicit stimulants, hallucinogens, inhalants, solvents, and dissociatives via telephone interview. Independent pathway models (IPMs) and common pathway models (CPMs) partitioned the variance of drug use phenotypes into general and drug-specific genetic ( ), common environmental ( ), and unique environmental factors ( ). An IPM with one general and one general factor and a one-factor CPM provided comparable fit to the data. General factors accounted for 55% ( = 14%, = 41%) and 79% ( = 64%, = 15%) of the respective variation in POM and heroin use in the IPM, and 25% ( = 12%, = 8%, 5%) and 80% ( = 38%, = 27%, 15%) of the respective variation in POM and heroin use in the CPM. Across both models, POM emerged with substantial drug-specific genetic influence (26-39% of total phenotypic variance; 69-74% of genetic variance); heroin use did not (0% of total phenotypic variance; 0% of genetic variance in both models). Prescription sedative misuse also demonstrated significant drug-specific genetic variance. |
| CONCLUSIONS |
NlmCategory: CONCLUSIONS |
| Many studies aggregate prescription opioid misuse (POM) and heroin use into a single phenotype, but emerging evidence suggests that their genetic and environmental influences may be partially distinct. In total, 7164 individual twins (84.12% complete pairs; 59.81% female; mean age = 30.58 years) from the Australian Twin Registry reported their lifetime misuse of prescription opioids, stimulants, and sedatives, and lifetime use of heroin, cannabis, cocaine/crack, illicit stimulants, hallucinogens, inhalants, solvents, and dissociatives via telephone interview. Independent pathway models (IPMs) and common pathway models (CPMs) partitioned the variance of drug use phenotypes into general and drug-specific genetic ( ), common environmental ( ), and unique environmental factors ( ). An IPM with one general and one general factor and a one-factor CPM provided comparable fit to the data. General factors accounted for 55% ( = 14%, = 41%) and 79% ( = 64%, = 15%) of the respective variation in POM and heroin use in the IPM, and 25% ( = 12%, = 8%, 5%) and 80% ( = 38%, = 27%, 15%) of the respective variation in POM and heroin use in the CPM. Across both models, POM emerged with substantial drug-specific genetic influence (26-39% of total phenotypic variance; 69-74% of genetic variance); heroin use did not (0% of total phenotypic variance; 0% of genetic variance in both models). Prescription sedative misuse also demonstrated significant drug-specific genetic variance. Genetic variation in POM, but not heroin use, is predominantly drug-specific. Misuse of prescription medications that reduce experiences of subjective distress may be partially influenced by sources of genetic variation separate from illicit drug use. |
|
| DATE PUBLISHED |
|
|
| HISTORY |
|
| PUBSTATUS |
PUBSTATUSDATE |
| entrez |
2023/03/22 06:23 |
| pubmed |
2023/03/23 06:00 |
| medline |
2023/03/23 06:00 |
|
| AUTHORS |
|
| NAME |
COLLECTIVENAME |
LASTNAME |
FORENAME |
INITIALS |
AFFILIATION |
AFFILIATIONINFO |
| Dash GF |
|
Dash |
Genevieve F |
GF |
|
Department of Psychological Sciences, University of Missouri, Columbia, MO 65211, USA. |
| Gizer IR |
|
Gizer |
Ian R |
IR |
|
Department of Psychological Sciences, University of Missouri, Columbia, MO 65211, USA. |
| Martin NG |
|
Martin |
Nicholas G |
NG |
|
QIMR Berghofer, Brisbane, Queensland 4006, Australia. |
| Slutske WS |
|
Slutske |
Wendy S |
WS |
|
Department of Family Medicine and Community Health and Center for Tobacco Research and Intervention, University of Wisconsin, Madison, WI 53711, USA. |
|
| INVESTIGATORS |
|
|
| JOURNAL |
|
| VOLUME: |
| ISSUE: |
| TITLE: Psychological medicine |
| ISOABBREVIATION: Psychol Med |
| YEAR: 2023 |
| MONTH: Mar |
| DAY: 22 |
| MEDLINEDATE: |
| SEASON: |
| CITEDMEDIUM: Internet |
| ISSN: 1469-8978 |
| ISSNTYPE: Electronic |
|
| MEDLINE JOURNAL |
|
| MEDLINETA: Psychol Med |
| COUNTRY: England |
| ISSNLINKING: 0033-2917 |
| NLMUNIQUEID: 1254142 |
|
| PUBLICATION TYPE |
|
| PUBLICATIONTYPE TEXT |
| Journal Article |
|
| COMMENTS AND CORRECTIONS |
|
|
| GRANTS |
|
| GRANTID |
AGENCY |
COUNTRY |
| R37AA007728 |
NIAAA NIH HHS |
United States |
| R01DA18267 |
NIDA NIH HHS |
United States |
| R37 AA007728 |
NIAAA NIH HHS |
United States |
| R01 DA018267 |
NIDA NIH HHS |
United States |
| F31 DA054701 |
NIDA NIH HHS |
United States |
|
| GENERAL NOTE |
|
|
| KEYWORDS |
|
| KEYWORD |
| Drug use |
| heroin |
| multivariate |
| prescription opioids |
| twin study |
|
| MESH HEADINGS |
|
|
| SUPPLEMENTARY MESH |
|
|
| GENE SYMBOLS |
|
|
| CHEMICALS |
|
|
| OTHER ID's |
|
|
|
